NCT02533765View on ClinicalTrials.gov

Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 11, 2015

Primary Completion Date

September 30, 2018

Study Completion Date

February 13, 2023

Conditions

Neoplasms, Germ Cell and Embryonal

Interventions

DRUG

Olaparib

Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.

Trial Locations (2)

47014

U.O Oncologia Medica, IRST IRCCS, Meldola

80131

"Istituto Nazionale Tumori IRCCS Fondazione G.Pascale", Napoli

All Listed Sponsors

lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER

NCT02533765 - Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor | Biotech Hunter | Biotech Hunter